Risk Of Developing Liver Cancer After HCV Treatment

Saturday, April 14, 2018

International Liver Congress 2018: 8-weeks of Zepatier (elbasvir/grazoprevir) may effectively treat HCV genotype 4

8-weeks of Zepatier may effectively treat HCV genotype 4
April 14, 2018
PARIS — In patients with hepatitis C virus genotype 4, 8 weeks of Zepatier showed effective treatment of the virus, according to a presentation at the International Liver Congress 2018.

“This is an ongoing study investigating a novel 8-week treatment regimen of elbasvir/grazoprevir in participants with genotype 4 infection,” Tarik Asselah, MD, University Paris Diderot, said in his presentation. “We have high rates of SVR among treatment-naive participants with mild to moderate fibrosis who have completed follow up.”


Of Interest
Impact of HCV Viral Load on Elbasvir/Grazoprevir Effectiveness in Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network - (04/13/18)

All Updates @ Healio

All Updates @ NATAP

On This Blog
For Patients: The International Liver Congress 2018

No comments:

Post a Comment